The SNF2-like helicase HELLS mediates E2F3-dependent transcription and cellular transformation

EMBO Journal

Volumn 31, Issue 4, 2012, Pages 972-985

  Von Eyss, Björn ^a   Maaskola, Jonas ^a   Memczak, Sebastian ^a   Möllmann, Katharina ^a   Schuetz, Anja ^a   Loddenkemper, Christoph ^b   Tanh, Mai Dinh ^a   Otto, Albrecht ^a   Muegge, Kathrin ^c   Heinemann, Udo ^a   Rajewsky, Nikolaus ^a   Ziebold, Ulrike ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c SAIC FREDERICK INC   (United States)

Author keywords

cell cycle re entry; E2F3; H3K27me3; HELLS; prostate tumour

Indexed keywords

HELICASE; PROTEIN; PROTEIN MIXED LINEAGE LEUKAEMIA1; PROTEIN SNF2; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENICITY; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME BINDING; GENE; GENE CONTROL; GENE INDUCTION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENOME; HELLS GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR GROWTH;

CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; DNA HELICASES; E2F3 TRANSCRIPTION FACTOR; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; TRANSCRIPTION, GENETIC;

EID: 84857048728     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/emboj.2011.451     Document Type: Article

References (48)

1. Aslanian A, Iaquinta PJ, Verona R, Lees JA (2004) Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 18: 1413-1422 (Pubitemid 38780628)
2. Asp P, Acosta-Alvear D, Tsikitis M, van Oevelen C, Dynlacht BD (2009) E2f3b plays an essential role in myogenic differentiation through isoform-specific gene regulation. Genes Dev 23: 37-53
3. Bell O, Tiwari VK, Thomä NH, Schübeler D (2011) Determinants and dynamics of genome accessibility. Nat Rev Genet 12: 554-564
4. Blais A, Dynlacht BD (2007) E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol 19: 658-662 (Pubitemid 350216425)
5. Burkhart DL, Sage J (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671-682
6. Chong JL, Wenzel PL, Sáenz-Robles MT, Nair V, Ferrey A, Hagan JP, Gomez YM, Sharma N, Chen HZ, Ouseph M, Wang SH, Trikha P, Culp B, Mezache L, Winton DJ, Sansom OJ, Chen D, Bremner R, Cantalupo PG, Robinson ML et al (2009) E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 462: 930-934
7. Danielian PS, Friesenhahn LB, Faust AM, West JC, Caron AM, Bronson RT, Lees JA (2008) E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity. Oncogene 27: 6561-6570
8. DeGregori J, Johnson DG (2006) Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 6: 739-748 (Pubitemid 44725567)
9. Dennis K, Fan T, Geiman T, Yan Q, Muegge K (2001) Lsh, a member of the SNF2 family, is required for genome-wide methylation. Genes Dev 15: 2940-2944 (Pubitemid 33078944)
10. Fan T, Yan Q, Huang J, Austin S, Cho E, Ferris D, Muegge K (2003) Lsh-deficient murine embryonal fibroblasts show reduced proliferation with signs of abnormal mitosis. Cancer Res 63: 4677-4683 (Pubitemid 36951047)
11. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS, Cooper CS (2004) Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23: 1627-1630 (Pubitemid 38406526)
12. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS (2004) Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23: 5871-5879 (Pubitemid 39093531)
13. Halstrom TC, Nevins JR (2003) Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci USA 100: 10848-10853 (Pubitemid 37140116)
14. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674
15. Huang J, Fan T, Yan Q, Zhu H, Fox S, Issaq HJ, Best L, Gangi L, Munroe D, Muegge K (2004) Lsh, an epigenetic guardian of repetitive elements. Nucleic Acids Res 32: 5019-5028 (Pubitemid 39445488)
16. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA (2000) E2f3 is critical for normal cellular proliferation. Genes Dev 14: 690-703 (Pubitemid 30176823)
17. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA (2008) Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 27: 2716-2727 (Pubitemid 351581468)
18. Kong LJ, Chang JT, Bild AH, Nevins JR (2007) Compensation and specificity of function within the E2F family. Oncogene 26: 321-327 (Pubitemid 46122822)
19. Lang SE, McMahon SB, Cole MD, Hearing P (2001) E2F transcriptional activation requires TRRAP and GCN5 cofactors. J Biol Chem 276: 32627-32634
20. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR (2000) Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 20: 3626-3632 (Pubitemid 30243908)
21. Liu H, Cheng EH, Hsieh JJ (2007) Bimodal degradation of MLL by SCFSkp 2 and APCCdc 20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev 21: 2385-2398 (Pubitemid 47529369)
22. Liu W, Tanasa B, Tyurina OV, Zhou TY, Gassmann R, Liu WT, Ohgi KA, Benner C, Garcia-Bassets I, Aggarwal AK, Desai A, Dorrestein PC, Glass CK, Rosenfeld MG (2010) PHF8 mediates histone H4 lysine 20 demethylation events involved in cell cycle progression. Nature 466: 508-512
23. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD (1998) The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94: 363-374 (Pubitemid 28376080)
24. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P, BrockmanW, Kim TK, Koche RP, LeeW, Mendenhall E, O'Donovan A, Presser A, Russ C, Xie X, Meissner A, Wernig M, Jaenisch R, Nusbaum C et al (2007) Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448: 553-560 (Pubitemid 47206934)
25. Myant K, Stancheva I (2008) LSH cooperates with DNA methyltransferases to repress transcription. Mol Cell Biol 28: 215-226
26. Myant K, Termanis A, Sundaram AY, Boe T, Li C, Merusi C, Burrage J, de Las Heras JI, Stancheva I (2011) LSH and G9a/GLP complex are required for developmentally programmed DNA methylation. Genome Res 21: 83-94
27. Narita M, Nnez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716 (Pubitemid 36724935)
28. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, Firestein R, Cleary M, Jenuwein T, Herrera RE, Kouzarides T (2001) Rb targets histone H3 methylation and HP1 to promoters. Nature 412: 561-565 (Pubitemid 32743837)
29. Niu J, Chen T, Han L, Wang P, Li N, Tong T (2011) Transcriptional activation of the senescence regulator Lsh by E2F1. Mech Ageing Dev 132: 180-186
30. Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ, Sauter G (2004) E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23: 5616-5623 (Pubitemid 39093039)
31. Parisi T, Yuan TL, Faust AM, Caron AM, Bronson R, Lees JA (2007) Selective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chimeric tissues. Mol Cell Biol 27: 2283-2293 (Pubitemid 46418482)
32. Raabe EH, Abdurrahman L, Behbehani G, Arceci RJ (2001) An SNF2 factor involved in mammalian development and cellular proliferation. Dev Dyn 221: 92-105
33. Rayman JB, Takahashi Y, Indjeian VB, Dannenberg JH, Catchpole S, Watson RJ, te Riele H, Dynlacht BD (2002) E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev 16: 933-947 (Pubitemid 34408543)
34. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD (2002) E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 16: 245-256 (Pubitemid 34075816)
35. Saavedra HI, Maiti B, Timmers C, Altura R, Tokuyama Y, Fukasawa K, Leone G (2003) Inactivation of E2F3 results in centrosome amplification. Cancer Cell 3: 333-346 (Pubitemid 38340303)
36. Sawarkar R, Paro R (2010) Interpretation of developmental signaling at chromatin: the polycomb perspective. Dev Cell 19: 651-661
37. Simon M, Köster G, Menon AG, Schramm J (1999) Functional evidence for a role of combined CDKN2A (p16-p14ARF)/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropatho 98: 444-452 (Pubitemid 29476161)
38. Sun LQ, Lee DW, Zhang Q, Xiao W, Raabe EH, Meeker A, Miao D, Huso DL, Arceci RJ (2004) Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG. Genes Dev 18: 1035-1046 (Pubitemid 38620243)
39. Takahashi Y, Rayman JB, Dynlacht BD (2000) Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 14: 804-816 (Pubitemid 30215000)
40. Taubert S, Gorrini C, Frank SR, Parisi T, Fuchs M, Chan HM, Livingston DM, Amati B (2004) E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol Cell Biol 24: 4546-4556 (Pubitemid 44109137)
41. Tsai SY, Opavsky R, Sharma N, Wu L, Naidu S, Nolan E, Feria-Arias E, Timmers C, Opavska J, de Bruin A, Chong JL, Trikha P, Fernandez SA, Stromberg P, Rosol TJ, Leone G (2008) Mouse development with a single E2F activator. Nature 28: 1137-1141
42. Tyagi S, Chabes AL, Wysocka J, Herr W (2007) E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell 27: 107-119 (Pubitemid 46991384)
43. Van den Heuvel S, Dyson NJ (2008) Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol 9: 713-724
44. Waseem A, Ali M, Odell EW, Fortune F, Teh MT (2010) Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol 46: 536-542
45. Xi S, Zhu H, Xu H, Schmidtmann A, Geiman TM, Muegge K (2007) Lsh controls Hox gene silencing during development. Proc Natl Acad Sci 104: 14366-14371 (Pubitemid 350003267)
46. Yan Q, Cho E, Lockett S, Muegge K (2003) Association of Lsh, a regulator of DNA methylation, with pericentromeric heterochromatin is dependent on intact heterochromatin. Mol Cell Biol 23: 8416-8428 (Pubitemid 37433350)
47. Zhu H, Geiman TM, Xi S, Jiang Q, Schmidtmann A, Chen T, Li E, Muegge K (2006) Lsh is involved in de novo methylation of DNA. EMBO J 25: 335-345 (Pubitemid 43152854)
48. Ziebold U, Lee EY, Bronson RT, Lees JA (2003) E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Mol Cell Biol 23: 6542-6552 (Pubitemid 37075765)